Drug Profile
Malaria vaccine live attenuated - Sanaria
Alternative Names: Pf delta b9 delta Slarp; PfSPZ malaria vaccine live attenuated - Sanaria; PfSPZ Vaccine - Sanaria; PfSPZ-GA1; Pf∆b9∆Slarp; Plasmodium falciparum sporozoite vaccine live attenuated - Sanaria; Sanaria PfSPZ VaccineLatest Information Update: 07 Nov 2023
Price :
$50
*
At a glance
- Originator Sanaria
- Developer National Institute of Allergy and Infectious Diseases; PATH; Sanaria
- Class Attenuated vaccines; Malaria vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Falciparum malaria
Most Recent Events
- 25 Oct 2022 Sanaria in collaboration with University of Maryland, Baltimore initiates enrolment in a phase I trial for Falciparum malaria (Prevention, In volunteers) in USA (IV) (NCT05604521)
- 28 Jul 2022 Sanaria and Fred Hutchinson Cancer Research Center completes a phase I trial for Falciparum malaria (Prevention) in USA (IV) (NCT04966871)
- 07 May 2022 Phase-II clinical trials in Falciparum malaria (Prevention, In adults) in Indonesia (IV) (NCT03503058)